Olainfarm has a good first quarter
This article was originally published in Scrip
Latvia's second-largest pharmaceutical manufacturer Olainfarm reported a net profit of €663,000 in the first quarter of this year compared with a €506,000 loss in the same period of 2008. Its earnings before interest and tax were €821,000, compared with the €279,000 loss in the same period last year.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.